The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial.

Sci Rep · 2021 · PMC8253801 · PMID 34215766

Europe PMC DOI

hedged sentence

0.0700

closest p · 1.4× alpha

0.0700

boldest claim

The sentences

not fully statistically significantp = 0.07so close (0.05 < p ≤ 0.1)

We found some evidence of longer mOS in patients with HER2-positivity gain in the metastatic setting, although at a not fully statistically significant extent ( p = 0.07).

also in 17 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.